Shanghai Pulmonary Hospital, Shanghai, China: clinical-trial pipeline
Shanghai Pulmonary Hospital, Shanghai, China is the sponsor of 157 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 79 are not yet finished and 5 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 73 |
| Phase 2 | 58 |
| Phase 4 | 16 |
| Phase 3 | 8 |
| Phase 2/3 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 57 |
| Recruiting | 38 |
| Not yet recruiting | 37 |
| Completed | 19 |
| Active, not recruiting | 4 |
| Terminated | 1 |
| Withdrawn or not authorised | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 98 |
| Respiratory | 37 |
| Infectious disease and vaccines | 13 |
| Cardiovascular | 3 |
| Neurology | 2 |
| Rare and genetic diseases | 2 |
| Dermatology | 1 |
| Metabolic and endocrine (diabetes, obesity) | 1 |
| Nephrology and urology | 1 |
| Women's health and obstetrics | 1 |
Countries
| Country | Trials |
|---|---|
| China | 120 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-15 | New trial posted | Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC |
| 2026-10-13 | New trial posted | Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Tri… |
| 2026-10-07 | New trial posted | Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclona… |
| 2026-09-16 | New trial posted | T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthm… |
| 2026-09-15 | New trial posted | Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults Wit… | Phase 4 | Recruiting | China |
| NCT07595120 | Application of Electromagnetic Navigation System in Pulmonary Nodule Localization | Not applicable | Not yet recruiting | China |
| NCT06620822 | Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved M… | Phase 2 | Not yet recruiting | China |
| NCT07494591 | TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery | Not applicable | Not yet recruiting | China |
| NCT06772610 | The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Ri… | Phase 2 | Not yet recruiting | |
| NCT06591910 | Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung… | Not applicable | Not yet recruiting | |
| NCT06293690 | Toripalimab Combined With SBRT for NSCLC | Phase 2 | Active, not recruiting | China |
| NCT07820254 | Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients | Not applicable | Recruiting | China |
| NCT06480136 | SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First… | Phase 2 | Not yet recruiting | |
| NCT07129629 | Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-… | Phase 2 | Not yet recruiting | |
| NCT07493980 | Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell… | Phase 2 | Not yet recruiting | China |
| NCT06528847 | Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma | Phase 2 | Recruiting | China |
| NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | Not applicable | Recruiting | China |
| NCT07375979 | A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a… | Not applicable | Not yet recruiting | China |
| NCT07153770 | Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung… | Phase 2 | Not yet recruiting | |
| NCT07823842 | T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD | Not applicable | Recruiting | China |
| NCT06652555 | The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-po… | Not applicable | Not yet recruiting | |
| NCT06109402 | Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | China |
| NCT04685070 | Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-sma… | Phase 2 | Active, not recruiting | China |
| NCT03351842 | Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% | Phase 2 | Recruiting | China |
| NCT05881057 | Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer | Not applicable | Not yet recruiting | |
| NCT07243873 | Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational… | Not applicable | Recruiting | China |
| NCT06496009 | The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patien… | Not applicable | Not yet recruiting | |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients… | Phase 4 | Not yet recruiting | China |
| NCT07323056 | Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small C… | Phase 2 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Shanghai Pulmonary Hospital, Shanghai, China clinical trials: 79 open, 10 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/shanghai-pulmonary-hospital-shanghai-china/, data as of 2026-10-25.